Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > technical analysis

<< Previous

Bullboard Posts

Next >>

Comment by MrVerbatim9800on Dec 22, 2020 7:00pm

453 Views

Post# 32166363

RE:technical analysis

These $4.40 units have been trading since Dec 15. Begining with a chunk of an even 1000,000 Sold on the 15th.......

mingzhu wrote: $3 has strong support, followed by $2. If it reaches 2, then the hot topic of psy medicine is over for some time. The broker cannot sell $4.40 shares to clients. but MMED will get the money anyway.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market